Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (Nasdaq: ECOR) is a commercial-stage bioelectronic medicine and wellness company that regularly issues news on its non-invasive neuromodulation technologies, prescription therapies, and wellness and performance devices. This news feed aggregates company press releases, clinical study announcements, reimbursement developments, corporate updates, and other disclosures directly related to electroCore.
Readers can follow updates on electroCore’s prescription products, including gammaCore non-invasive vagus nerve stimulation (nVNS) and the Quell neurostimulator for chronic pain syndromes, as well as its handheld Truvaga and TAC-STIM devices for general wellness and human performance. News items have covered peer-reviewed studies on gammaCore in persistent post-concussion symptoms, controlled trials of TAC-STIM in active-duty Air Force trainees, and recognition of Truvaga Plus in consumer-focused awards.
The ECOR news stream also includes financial and corporate information such as quarterly results, revenue trends, private placements, participation in investor conferences, and changes to the board of directors and executive team. Regulatory and market access milestones, like reimbursement decisions for gammaCore Sapphire in Belgium, appear alongside product and clinical updates.
Investors, clinicians, and individuals interested in bioelectronic medicine can use this page to review electroCore’s historical and recent announcements in one place. For deeper analysis of any item, users can combine these news releases with the company’s SEC filings and other official documents accessible through related sections of the platform.
electroCore (ECOR) has secured a new five-year Federal Supply Schedule (FSS) contract with the Veterans Affairs (VA), effective from June 15, 2025, through June 14, 2030. The renewal comes after the VA's termination of 585 non-mission critical contracts, highlighting gammaCore's strategic importance.
The company reported accelerated revenue from VA hospitals in February and March 2025, following a slight slowdown in January, indicating sustained demand for their drug-free migraine treatment solution. The new contract includes provisions for prompt pay discounts and volume rebates for revenues exceeding $10 million per calendar year.
electroCore (ECOR) reported record financial results for full year 2024, achieving net sales of $25.2 million, a 57% increase from $16.0 million in 2023. The growth was primarily driven by an 85% increase in Rx gammaCore sales through VA/DOD channels and a 174% rise in Truvaga sales.
The company's net loss decreased by 37% to $11.9 million in 2024, with gross profit reaching $21.4 million at an 85% margin. Operating expenses totaled $33.6 million, including $2.4 million in R&D and $31.2 million in SG&A costs. Cash burn improved significantly, with net cash used in operations decreasing 53% to $7.0 million.
The company ended 2024 with $12.2 million in cash and equivalents, up from $10.6 million at the end of 2023. The adjusted EBITDA net loss improved to $9.0 million from $15.4 million in the previous year.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has scheduled its fourth quarter and full year 2024 financial results announcement for Wednesday, March 12, 2025, after market close. The company will host a webcast and conference call at 5:30 PM EDT where management will discuss the financial results and conduct a Q&A session.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has announced its participation in two major investor conferences in March 2025.
The company will attend the 37th Annual Roth Conference from March 16-18 at the Laguna Cliffs Marriott Resort & Spa in Dana Point, California, where Chief Financial Officer Joshua Lev will host one-on-one meetings with investors.
Additionally, electroCore will participate in LSI USA '25 from March 17-21 at the Waldorf Astoria Monarch Beach Resort in Dana Point, California, where CFO Joshua Lev will manage the company's exhibition presence.
Interested investors can schedule meetings through their Roth or LSI representatives or by contacting FNK IR at ecor@fnkir.com.
electroCore (NASDAQ: ECOR) has announced a distribution agreement with Spark Biomedical Inc. to distribute Sparrow Ascent™ within certain Department of Veterans Affairs (VA) facilities. Sparrow Ascent is an FDA-cleared non-invasive transcutaneous auricular neuromodulation device prescribed for treating opioid withdrawal symptoms.
The partnership aims to leverage electroCore's established distribution network to expand access to this drug-free, wearable neurostimulation solution for veterans. The Sparrow Ascent therapy complements electroCore's existing gammaCore™ therapy portfolio, offering VA customers a non-addictive treatment option for opioid withdrawal symptoms.
electroCore (NASDAQ: ECOR) has announced the availability of its flagship wellness product, Truvaga Plus, on Amazon's retail platform. The hand-held vagus nerve stimulator is designed to provide stress relief, improve sleep, enhance peace of mind, and improve focus through gentle vagus nerve activation.
CEO Dan Goldberger highlighted that the Amazon listing will help showcase their product to a broader audience through America's largest e-commerce marketplace, potentially increasing consumer accessibility and adoption.
electroCore (Nasdaq: ECOR) has strengthened its intellectual property portfolio with two new U.S. patents granted by the USPTO. The first patent (No. 12,208,263), issued on January 28, 2025, covers methods for vagal nerve stimulation using electrodes with conductive gel on the neck, including position adjustment based on pressure sensation.
The second patent (No. 12,213,795), issued on February 4, 2025, relates to systems and methods for nerve modulation that incorporate data storage of electrical impulse parameters and patient monitoring, including the ability to track user status data such as headache severity.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has announced its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The event is scheduled for February 11-12, 2025 in Snowbird, Utah.
CEO Dan Goldberger will be available for one-on-one meetings throughout the conference. Interested investors can arrange meetings through their BTIG representative or by contacting electroCore's investor relations team directly at investors@electrocore.com.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced the issuance of five new U.S. patents by the USPTO between December 17, 2024, and December 31, 2024.
These patents include:
- US Patent No. 12,168,128 - Issued on December 17, 2024, it covers systems and methods for treating medical conditions by transmitting electrical impulses to the trigeminal nerve, controlled via a mobile device.
- US Patent No. 12,168,121 - Also issued on December 17, 2024, it relates to treating developmental disorders in fetuses by delivering electrical impulses to a nerve in pregnant women.
- US Patent No. 12,172,015 - Issued on December 24, 2024, it involves a medical device generating electrical impulses and using a smart card for refilling the device after specific usage.
- US Patent No. 12,172,016 - Issued on December 24, 2024, it pertains to non-invasive vagal nerve stimulation for treating Parkinson's disease.
- US Patent No. 12,179,012 - Issued on December 31, 2024, it describes a device for non-invasive nerve stimulation, transmitting electrical impulses through the skin to a target nerve.
These patents enhance electroCore's intellectual property portfolio, potentially strengthening its market position in bioelectronic medicine.
electroCore (ECOR) has announced a definitive agreement to acquire NeuroMetrix (NURO), focusing on its Quell platform while excluding the DPNCheck business. The acquisition aims to strengthen electroCore's position in the bioelectronic health and wellness sector. Quell is a wearable neuromodulation platform FDA-authorized for fibromyalgia symptoms and lower-extremity chronic pain treatment.
The transaction value will equal NURO's net cash balance at closing, with NURO shareholders receiving non-tradeable contingent value rights (CVRs). Each CVR includes rights to DPNCheck divestiture proceeds and up to $500,000 in Quell product royalties over two years post-closing. The deal is expected to close by Q1 2025, subject to NURO shareholder approval.
NeuroMetrix reported Q3 2024 results with total revenue of $600,000, including Quell revenue of $184,000 (50% YoY increase), and a net loss of $1.5 million.